CAR-T therapy immunotherapy technique used to kill tumor cells by genetically modified T-cells.[9] In principle T cells modified by chimeric antigen receptors can kill target cells by specifically recognizing target antigens, independent of the major histocompatibility complex.[10] CD56, a member of the immunoglobulin superfamily is a biomarker of Neural-Cell Adhesion Molecule and NK cells.[11] The positive expression rate of CD56 in skeletal muscle tumors and peripheral neurogenic tumors was significantly higher than that in smooth muscle tumors and other spindle cell tumors.[12]. The gene discussed is NCAM1; the disease is skeletal muscle neoplasm.